Prolight on track for clinical performance studies

Prolight Diagnostics, developer of the digital point-of-care platform Psyros™, announces today that their latest data for troponin in whole blood confirm that the company is now ready to initiate trials with patient samples. The latest data were generated in whole blood samples on the final commercial cartridge design, which now includes internal cartridge quality controls […]

Prolight initiates trial at London hospital Trust supported by an NIHR i4i PDA grant

Prolight Diagnostics today announces the company will initiate a trial at Guy’s and St Thomas’NHS Foundation Trust and King’s College London to pre-validate assay and prototype performance of the Psyros™ POC system. The trial is supported by the recently awarded NIHR i4i PDA grant. Initial data with patient samples will be generated in Q3 2024 […]

Prolight Diagnostics awarded SEK17M UK government grant in collaboration with leading UK hospital Trust

Prolight Diagnostics, developer of the digital point-of-care platform PsyrosTM, has been awarded an NIHR Invention for Innovation (i4i) Product Development Award (PDA) of SEK17M (£1.26M) in collaboration with among others, Guy’s and St Thomas’ NHS Foundation Trust, and King’s College London. “We are delighted to have been awarded this prestigious grant. The National Institute for […]

Prolight selects MDx CRO for the clinical performance studies for Psyros™

Prolight Diagnostics, developer of the digital point-of-care platform Psyros™, has appointed MDx CRO as its contract research partner for the clinical performance study to validate the Psyros™ high-sensitivity troponin test. After a rigorous selection process, Prolight is pleased to announce the appointment of MDxCRO as its clinical partner. The collaboration will focus on the clinical validation […]

Emergers publishes updated analysis about Prolight Diagnostics

Read the full article at: For further information, please contact:Prolight Diagnostics AB (publ)E-mail: info@prolightdx.comTelephone: +46 73 582 39 87Website: About UsProlight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood.We want to offer the foremost POC […]

Prolight finalizes commercial cartridge design

Prolight Diagnostics AB (publ), developer of the digital point-of-care platform Psyros™, today announces the finalization of the cartridge design to be used on the commercial platform. Now, the process of design transfer to Prolight’s contract manufacturing partner Flex Medical Solutions begins. Flex Medical will use the design for the pilot manufacturing processes which shall be be […]

Prolight announces positive accounting adjustments for the full year 2023

Prolight Diagnostics, developer of the digital point-of-care platform Psyros™, announced today that the company’s 2023 year-end release contains an understated claim on the UK tax authority related to research and development. The revised estimate of Prolight’s claim is approximately SEK 5.6 million higher than previously reported. In the annual report for 2023, which will be […]

Prolight Diagnostics selects FlexMedical Solutions as CMO partner

Prolight Diagnostics, developer of the digital point-of-care platform Psyros™, has appointed FlexMedical Solutions (FlexMedical) as its chosen Contract Manufacturing partner for the Psyros™ disposable cartridge. “The partnership is a major step in the development of the pilot manufacturing capabilities utilizing FlexMedical’s existing fully validated facilities and extensive IVD experience. One of the unique selling points […]

Emergers initiates equity research coverage of Prolight Diagnostics

Equity research firm Emergers has initiated coverage of Prolight Diagnostics. Excerpt from the equity research report: Having already achieved proof-of-performance for its proprietary digital technique for detection of high-sensitive biomarkers in low concentrations by counting single molecules, Prolight’s first objective is now to pioneer the Point-of-Care (POC) troponin market. Next steps involve prototype development and […]